Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25237125 | 0.78 | PI4KA (0.63) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL256211 | 0.78 | PI4KA (0.63) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL4087719 | 0.77 | PI4KA (0.37) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL2303091 | 0.77 | NPC1 (0.51) | SMN1; SMN2KDM4EALOX15MEN1KMT2A | |
| SCHEMBL4379601 | 0.76 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL130407 | 0.76 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL12826084 | 0.76 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL25605061 | 0.76 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL22521558 | 0.76 | ABL1 (0.45) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL11595465 | 0.76 | SIGMAR1 (0.43) | SMN1; SMN2PKMHTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | BREYE THERAPEUTICS APS (DK) | 2026-02-10 | — | — | US | disclosed |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250197421-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | 1CBIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| CN-120091811-A | Integrin inhibitors and their use in combination with other agents | 普利安特治疗公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4551204-A2 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | Pliant Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4525866-A1 | STABILIZATION OF INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2008063232-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| WO-2007062805-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-6946478-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-09-20 | — | — | US | disclosed |
| US-20030134840-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2003-07-17 | — | — | US | disclosed |
| US-6518286-B1 | Piperidinyl compounds for modulation of immune and inflammatory responses in various diseases and disorders, including asthma | ASTRAZENECA AB (SE) | 2003-02-11 | — | — | US | disclosed |
| US-6423716-B1 | Nitrogenous heterocyclic compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-07-23 | — | — | US | disclosed |
| EP-1067123-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
| US-4124764-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1978-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134840-A1 | Novel compounds | RPS4X, RPS4Y1, CYP4B1 | PI4KA 2930/4885PI4K2B 2677/4885PI4K2A 2989/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | PI4KA 2364/4885PI4K2B 2929/4885PI4K2A 2891/4885 |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, NCEH1 | PI4KA 2930/4885PI4K2B 2035/4885PI4K2A 2620/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | PI4KA 1052/4885PI4K2B 1572/4885PI4K2A 1661/4885 |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | ENPP1, ENPP3, ENPP2 | PI4KA 978/4885PI4K2B 1266/4885PI4K2A 1265/4885 |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | PI4KA 1309/4885PI4K2B 1135/4885PI4K2A 1243/4885 |
| US-20250197421-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | PI4KA 1791/4885PI4K2B 1754/4885PI4K2A 2302/4885 |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | PI4KA 1310/4885PI4K2B 1603/4885PI4K2A 1736/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | PI4KA 500/4885PI4K2B 371/4885PI4K2A 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.